Published On: Wed, Oct 19th, 2016

Latest Analyst Reports On Infinity Pharmaceuticals, Inc.


Recently stock market analysts have updated their consensus ratings on shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI).

Most recent broker ratings

08/10/2016 – Infinity Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Wedbush. They now have a USD 1 price target on the stock.

06/28/2016 – Infinity Pharmaceuticals, Inc. had its “market perform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 2 price target on the stock.

06/15/2016 – Infinity Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at JMP Securities.

06/15/2016 – Infinity Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at Wells Fargo.

06/15/2016 – Infinity Pharmaceuticals, Inc. was downgraded to “market perform” by analysts at William Blair. They now have a USD 2 price target on the stock.

06/15/2016 – Infinity Pharmaceuticals, Inc. was downgraded to “sector perform” by analysts at RBC Capital. They now have a USD 2 price target on the stock.

06/15/2016 – Infinity Pharmaceuticals, Inc. was downgraded to “equal weight” by analysts at Morgan Stanley. They now have a USD 1 price target on the stock.

06/15/2016 – Infinity Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Jefferies.

06/14/2016 – Infinity Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at JP Morgan.

05/14/2015 – Infinity Pharmaceuticals, Inc. had its “hold” rating reiterated by analysts at Stifel Nicolaus.

05/08/2015 – Infinity Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Nomura. They now have a USD 13 price target on the stock.

05/07/2015 – Deutsche Bank began new coverage on Infinity Pharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 20 price target on the stock.

04/30/2015 – Infinity Pharmaceuticals, Inc. was downgraded to “hold” by analysts at Zacks.

12/04/2014 – Infinity Pharmaceuticals, Inc. was upgraded to “outperform” by analysts at Credit Suisse. They now have a USD 22 price target on the stock.

09/03/2014 – Infinity Pharmaceuticals, Inc. had its “positive” rating reiterated by analysts at Roth Capital.

Infinity Pharmaceuticals, Inc. has a 50 day moving average of 1.49 and a 200 day moving average of 2.95. The stock’s market capitalization is 67.93M, it has a 52-week low of 1.24 and a 52-week high of 10.85.

The share price of the company (NASDAQ:INFI) was up +2.24%, with a high of 1.40 during the day and the volume of Infinity Pharmaceuticals, Inc. shares traded was 146963.